Chopin P, Moret C, Briley M
Division of Neurobiology I, Pierre Fabre Research Center, Castres, France.
Pharmacol Ther. 1994;62(3):385-405. doi: 10.1016/0163-7258(94)90051-5.
In spite of a lack of compounds acting selectively at the 5-hydroxytryptamine (5-HT)1B and 5-HT1D receptor subtypes, by cross-relating the available data, this review attempts to tentatively assign behavioural and other in vivo correlates of these receptor subtypes. In addition, a summary of data from microdialysis studies is included to develop an integrated view. Finally, a suggestion is made as to the possible pathophysiological consequences of 5-HT1D receptor dysfunction in man.
